Authors' objectives:

To summarise the current research evidence on T-20 for HIV.

Authors' recommendations: - Clinical impact: T-20 is a novel product to slow the progression of HIV infection. If early clinical trial results are confirmed, T-20 may have a significant clinical impact at least in the short term. - Service impact: Although it is difficult to estimate at this time, there is unlikely to be a significant service impact associated with the introduction of T-20 for HIV. - Additional factors: Due to the nature of HIV and the size of the patient group failing therapy at all levels, there may be a significant patient interest in the introduction of T-20 for HIV. - Financial and overall NHS impact: Due to the lack of cost data it is difficult to estimate the likely financial impact at this time. However, due to the potential size of the patient group the introduction of T-20 for HIV may have a significant financial impact.

Authors' methods: Overview

Project Status: Completed

Year Published: 2002

URL for published report: http://www.hsric.nihr.ac.uk/search

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: National Horizon Scanning Centre (NHSC)